	US 11,673,939 B2
	Compositions and methods for diagnosis and treatment of cancer
Ugur Sahin, Mainz (DE); Bonny Gaby Lui, Mainz (DE); Nadja Salomon, Hochheim (DE); Joycelyn Wüstehube-Lausch, Mainz (DE); Matin Daneschdar, Mainz (DE); Hans-Ulrich Schmoldt, Mainz (DE); and Markus Fiedler, Halle (DE)
Assigned to BIONTECH SE
Appl. No. 16/972,794
Filed by BioNTech SE, Mainz (DE)
PCT Filed Jun. 6, 2019, PCT No. PCT/EP2019/064872 § 371(c)(1), (2) Date Dec. 7, 2020, PCT Pub. No. WO2019/234190, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. PCT/EP2018/065205 (WO), filed on Jun. 8, 2018.
Prior Publication US 2021/0246191 A1, Aug. 12, 2021
Int. Cl. C07K 14/78 (2006.01); C07K 1/107 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/78 (2013.01) [C07K 1/1075 (2013.01); G01N 33/574 (2013.01); G01N 33/68 (2013.01); A61K 38/00 (2013.01)]

19 Claims

1. A Fibronectin Extra Domain B (EDB) binding peptide which comprises the amino acid sequence:

(Xaa)n1 Cys (Xaa)n2 Arg Ile/Val Arg Leu(Xaa)n3 Cys (Xaa)n4 Cys (Xaa)n5 Cys (Xaa)n6 Cys (Xaa)n7 Cys (Xaa)n8 (SEQ ID NO: 4)

wherein

the Cys residues form a cystine knot structure,

each Xaa is independently any amino acid, and

n1, n2, n3, n4, n5, n6, n7, and n8 are the respective numbers of amino acids, wherein

n1 is 0 to 4,

n2 is 3 to 10,

n3 is 0 to 3,

n4 is 3 to 7,

n5 is 2 to 6,

n6 is 1 to 3,

n7 is 3 to 7,

n8 is 0 to 4, and

each amino acid Xaa and the number of amino acids n1, n2, n3, n4, n5, n6, n7 and n8 are selected such that a cystine knot structure can form between the Cys residues.